News articles featuring quotes from Real Endpoints

<>

April 9, 2018

BioCentury

Part D Sour Spot

by Steve Usdin

A law that comes into effect next year will squeeze profits from moderately priced drugs that treat common, chronic conditions and increase economic incentives to develop high priced medicines for rare or acute life-threatening diseases. Manufacturers of drugs to treat common, chronic conditions will be especially hard hit.

read full article >

March 8, 2018

Financial Times

Cigna grabs vital scale with $67bn deal for Express Scripts

by David Crow

Express Scripts was the last large independent pharmacy benefits manager, or PBM, in the US. A PBM acts as a middleman in negotiations between drugmakers and the payers (i.e. employers, insurers, and government), which buy medicines in the US. With its $67 billion takeover of Express Scripts, health insurer Cigna is sending a signal that it will have to get bigger to deal with the most pressing malady of US healthcare: soaring costs. By buying Express Scripts, Cigna hopes to gain more scale so it can drive a harder bargain when buying drugs and services, not just from pharmaceutical companies, but also the doctors and hospitals that provide patient care.

read full article >

March 5, 2018

BioCentury

De-Risking Risk Reduction

by Erin McCallister

A first-of-its kind value deal between Illumina Inc. and Harvard Pilgrim Health Care Inc. is intended to generate data to support broad reimbursement by multiple payers for non-invasive prenatal tests made by multiple testing companies.

read full article >

January 31, 2018

In Vivo

Biopharma 2018: Is there still a place for pharma in the new health care economy?

by William Looney

Biopharma is not moving as quickly in 2018 as its counterparts in adjacent industry segments, and is confronting a strategic dilemma on how to address the prospect of a much more powerful set of rivals in the ongoing battle to own the patient experience in medicine.

read full article >

December 1, 2017

Scrip

Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha

by Emily Hayes

Labeling for reduction of cardiovascular risk may help a bit with payers, but the "twin problem" of pricing and lack of patient adherence is likely to continue to present hurdles for reimbursement.

read full article >

November 20, 2017

In Vivo

Proving the Value of Value-Based Deals

by Ed Silverman

As controversy continues over pharmaceutical pricing, more drugmakers are eyeing deals that peg health plan cost to outcomes to boost volume and win formulary placement. But these deals are challenging to construct and to date there is little evidence that they reduce costs for patients.

read full article >